Bayer Appeals Yasmin Contraceptive Patent Invalidity

Law360, New York (March 31, 2008, 12:00 AM EDT) -- Bayer Schering Pharma AG has appealed a judge's recent finding that the patent at issue in the lawsuit against Barr Laboratories Inc. over the $488 million U.S. market for the contraceptive Yasmin is invalid due to obviousness.

The notice of appeal was filed Monday in the U.S. District Court for the District of New Jersey. In early March, U.S. District Judge Peter G. Sheridan dismissed the case, holding that the asserted claims of the patent-in-suit were invalid because they would have been obvious to a person...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.